Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-directacting antiviral era: A path forward: Editorial on “Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication”

키워드

참고문헌 (20)

1. Singal AG, "Global trends in hepatocellular carcinoma epidemiology : implications for screening, prevention and therapy", Nat Rev Clin Oncol, 20, pp.864~884 (2023)
2. Su F, "Hepatocellular carcinoma risk after directacting antiviral therapy", Clin Liver Dis(Hoboken), 13, pp.6~12 (2019)
3. Huang CF, "Unmet needs in the post-direct-acting antivirals era : The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication", Clin Mol Hepatol, 30, pp.326~344 (2024)
4. Dhanasekaran R, "Molecular and immune landscape of hepatocellular carcinoma to guide therapeutic decision-making", Hepatology (2023)[DOI]
5. Li S, "The prognostic value of AT-rich interaction domain(ARID)family members in patients with hepatocellular carcinoma", Evid Based Complement Alternat Med, 2022, pp.1150390~ (2022)
6. Haque E, "Molecular mechanisms underlying hepatocellular carcinoma induction by aberrant NRF2 activationmediated transcription networks : Interaction of NRF2-KEAP1controls the fate of hepatocarcinogenesis", Int J Mol Sci, 21, pp.5378~ (2020)
7. Thomas CE, "NAFLD polygenic risk score and risk of hepatocellular carcinoma in an East Asian population", Hepatol Commun, 6, pp.2310~2321 (2022)
8. Wolf E, "Use of hepatocellular carcinoma surveillance in patients with cirrhosis : A systematic review and meta-analysis", Hepatology, 73, pp.713~725 (2021)
9. Singal AG, "AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma", Hepatology, 78, pp.1922~1965 (2023)
10. Omata M, "Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma : a 2017 update", Hepatol Int, 11, pp.317~370 (2017)
11. Teng W, "Management consensus guidelines for hepatocellular carcinoma: 2023 Update on surveillance, diagnosis, systemic treatment, and posttreatment monitoring by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan", Liver Cancer (2024)[DOI]
12. European Association for the Study of the Liver, "EASL Clinical Practice Guidelines : Management of hepatocellular carcinoma", J Hepatol, 69, pp.182~236 (2018)
13. Huang DQ, "Hepatocellular carcinoma surveillance-utilization, barriers and the impact of changing aetiology", Nat Rev Gastroenterol Hepatol, 20, pp.797~809 (2023)
14. Dajti E, "Risk of hepatocellular carcinoma after HCV eradication : Determining the role of portal hypertension by measuring spleen stiffness", JHEP Rep, 3, pp.100289~ (2021)
15. Dabbish AM, "Prognostic MicroRNA Panel for HCV-Associated HCC : Integrating Computational Biology and Clinical Validation", Cancers(Basel), 14, pp.3036~ (2022)
16. Semmler G, "HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease", J Hepatol, 76, pp.812~821 (2022)
17. Ioannou GN, "Assessment of a deep learning model to predict hepatocellular carcinoma in patients with hepatitis C cirrhosis", JAMA Netw Open, 3, pp.e2015626~ (2020)
18. Lockart I, "HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis : A meta-analysis", Hepatology, 76, pp.139~154 (2022)
19. Farhang Zangneh H, "Cost effectiveness of hepatocellular carcinoma surveillance after a sustained virologic response to therapy in patients with hepatitis C virus infection and advanced fibrosis", Clin Gastroenterol Hepatol, 17, pp.1840~1849 (2019)
20. Dhanasekaran R, "Hepatitis C and hepatocellular cancer : To treat or not to treat", Clin Liver Dis(Hoboken), 17, pp.169~173 (2021)

관련 논문AI추천